The Developing Countries Interest Group (DCIG) and the Patient and Citizen Involvement Interest Group (PCIG) of HTAi (Health Technology Assessment international; www.htai.org) are currently collaborating in a project with the objective to (1) explore the current routes of patient involvement in Low-and Middle Income Countries (LMICs), (2) collaborate with LMIC stakeholders to define LMIC-specific needs […]
All posts by: Anke
FiercePharma, by Eric Sagonowsky, Apr 10, 2019 For years, drugmakers and PBMs have tussled over who’s to blame for high drug prices. That didn’t change Tuesday when a congressional committee hauled in executives from insulin makers Sanofi, Eli Lilly and Novo Nordisk as well as from pharmacy benefit managers CVS, Express Scripts and Optum. Going […]
FierceBiotech by Conor Hale, Apr 9, 2019 Concerto HealthAI has inked its second real-world data collaboration with a Big Pharma company in as many weeks, this time to help Pfizer select patients for its precision oncology development work. Concerto, a SymphonyAI company, aims to design more efficient clinical trials using prefabricated control arms and data […]
FiercePharma, by Angus Liu, Feb 13, 2019 Playing catch-up in the orphan drug field, China will cut the value-added tax rate for some rare-disease therapies by more than 80% in an effort to get new treatments to market faster. And multinational drugmakers are most likely to reap the benefits. Starting March 1, the value-added tax […]
FiercePharma, by Arlene Weintraub, Jan 25, 2019 AbbVie investors have been bracing for the mother of all patent cliffs—the loss of exclusivity on the company’s $18-billion-per-year Humira—and now its impact is starting to come into view. The mass exodus from the branded product to biosimilars confirms what AbbVie’s executives have already admitted, which is that their […]
FiercePharma, by Carly Helfand, Jan 28, 2019 AstraZeneca has struck a deal with UPMC Health Plan (USA) that links reimbursement for the blood thinner, which is approved to cut the risk of death or a second heart attack in people who have already had one, to patients’ cardiovascular outcomes—the usual trade-off for a value-based deal. But […]
FiercePharma, by Arlene Weintraub, Jan 29, 2019 When Dave Lennon, president of Novartis unit AveXis, said in November that the company’s experimental gene therapy to treat spinal muscular atrophy (SMA) could be cost-effective at a price of $4 million to $5 million, some pricing critics immediately raised red flags. But then the Institute for Clinical […]
FiercePharma, by Angus Liu, Jan 29, 2019 Pfizer has launched China’s first pay-for-performance program in oncology with its blockbuster breast cancer drug Ibrance, China Daily reported. Under the new program, called Bo’ai Xin’an, Pfizer promises reimbursement of up to 33.5% of Ibrance costs if an enrolled patient’s disease progresses within four months. The U.S. pharma set […]
19. April 2018 Interview with Anke Holtorf, Managing Director, Health Outcomes Strategies, GmbH on the subject of patient involvement in pharmaceutical market access. Patients are playing an increasingly powerful part in market access, and this was recently explored within a chapter in the newly-published book Pharmaceutical Market Access in Developed Countries. For full text see http://patientfocusedmedicine.org/integrating-patient-insights-challenges-and-opportunities/
We would like to use the opportunity to share with you the link to a new book which has finally been released (fresh from the electronic press!) and to which Anke-Peggy Holtorf has contributed two chapters (“Market Access in Germany” and, together with Nigel Cook, “The Role of Patients in Market Access“). Kockaya G, […]